Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 antagonist 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease

Journal of Pharmacology and Experimental Therapeutics

Volumn 333, Issue 3, 2010, Pages 865-873

  Johnston, Tom H ^a   Fox, Susan H ^b,c   McIldowie, Matthew J ^d   Piggott, Matthew J ^d   Brotchie, Jonathan M ^a  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; BENSERAZIDE PLUS LEVODOPA; LEVODOPA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE TITRATION; DRUG EFFECT; DRUG HALF LIFE; DRUG MECHANISM; DYSKINESIA; EXPERIMENTAL MODEL; FEMALE; LIQUID CHROMATOGRAPHY; MACACA; MALE; MASS SPECTROMETRY; MONKEY; MONOTHERAPY; MOTOR ACTIVITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIPARKINSON AGENTS; BEHAVIOR, ANIMAL; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MACACA FASCICULARIS; MALE; MOTOR ACTIVITY; MPTP POISONING; PARKINSON DISEASE, SECONDARY; PIPERIDINES; RECEPTORS, METABOTROPIC GLUTAMATE; THIAZOLES;

EID: 77952382801     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.166629     Document Type: Article

References (55)

1. Berg D, Godau J, Trenkwalder C, Eggert K, Csoti I, Storch A, Gasparini F, Hariry S, Johns DG, and Gomez-Mancilla B (2009) A randomized, controlled trial evaluating AFQ056 in reducing levodopa-induced dyskinesia in patients with Parkinson's disease (Abstract LB-05), in Proceedings of the Movement Disorder Society's 13th International Congress of Parkinson's Disease and Movement Disorders; 2009; June 7-11; Paris, France. Movement Disorder Society, Milwaukee, WI.
2. Bezard E, Brotchie JM, and Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci 2:577-588. (Pubitemid 33679831)
3. Bibbiani F, Oh JD, Kielaite A, Collins MA, Smith C, and Chase TN (2005) Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Exp Neurol 196:422-429. (Pubitemid 41607831)
4. Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, and Chase TN (1999) Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl- tetrahydropyridine monkeys. J Pharmacol Exp Ther 290:1034-1040. (Pubitemid 29400241)
5. Breysse N, Amalric M, and Salin P (2003) Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats. J Neurosci 23:8302-8309. (Pubitemid 37129647)
6. Breysse N, Baunez C, Spooren W, Gasparini F, and Amalric M (2002) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 22:5669-5678. (Pubitemid 35386488)
7. Brotchie JM, Lee J, and Venderova K (2005) Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm 112:359-391.
8. Busse CS, Brodkin J, Tattersall D, Anderson JJ, Warren N, Tehrani L, Bristow LJ, Varney MA, and Cosford ND (2004) The behavioral profile of the potent and selective mGlu5 receptor antagonist 3-[(2-methyl-1,3-thiazol-4-yl) ethynyl]pyridine (MTEP) in rodent models of anxiety. Neuropsychopharmacology 29:1971-1979. (Pubitemid 39486548)
9. Calabresi P, Giacomini P, Centonze D and Bernardi G (2000) Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 47:S60-S68; discussion S68-S69. (Pubitemid 30192011)
10. Calon F, Morissette M, Ghribi O, Goulet M, Grondin R, Blanchet PJ, Bédard PJ, and Di Paolo T (2002) Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog Neuropsychopharmacol Biol Psychiatry 26:127-138. (Pubitemid 34045159)
11. Calon F, Rajput AH, Hornykiewicz O, Bédard PJ, and Di Paolo T (2003) Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol Dis 14:404-416. (Pubitemid 37543519)
12. Cenci MA (2007) Dopamine dysregulation of movement control in L-DOPA-induced dyskinesia. Trends Neurosci 30:236-243. (Pubitemid 46654236)
13. Chase TN and Oh JD (2000) Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci 23:S86-S91.
14. Conn PJ and Pin JP (1997) Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol 37:205-237. (Pubitemid 27238875)
15. Cosford ND, Tehrani L, Roppe J, Schweiger E, Smith ND, Anderson J, Bristow L, Brodkin J, Jiang X, McDonald I, et al. (2003) 3-[(2-Methyl-1,3- thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J Med Chem 46:204-206. (Pubitemid 36078139)
16. Crossman AR (1990) A hypothesis on the pathophysiological mechanisms that underlie levodopa- or dopamine agonist-induced dyskinesia in Parkinson's disease: implications for future strategies in treatment. Mov Disord 5:100-108.
17. Dekundy A, Pietraszek M, Schaefer D, Cenci MA, and Danysz W (2006) Effects of group I metabotropic glutamate receptors blockade in experimental models of Parkinson's disease. Brain Res Bull 69:318-326.
18. Encarnacion EV and Hauser RA (2008) Levodopa-induced dyskinesias in Parkinson's disease: etiology, impact on quality of life, and treatments. Eur Neurol 60:57-66.
19. Fabbrini G, Brotchie JM, Grandas F, Nomoto M, and Goetz CG (2007) Levodopa-induced dyskinesias. Mov Disord 22:1379-1389; quiz 1523.
20. Fahn S, Elton RL, and Members of the UPDRS Development Committee (1987) Unified Parkinson's disease rating scale, in Recent Developments in Parkinson's Disease (Fahn S, Marsden D, Goldstein M, and Calne DB eds) pp 153-163, 293-304, Macmillan Health Care Information, Florham, NJ.
21. Fox SH, Brotchie JM, and Lang AE (2008) Non-dopaminergic treatments in development for Parkinson's disease. Lancet Neurol 7:927-938.
22. Fox SH and Lang AE (2008) Levodopa-related motor complications- phenomenology. Mov Disord 23 (Suppl 3):S509-S514.
23. Goetz CG, Poewe W, Rascol O, and Sampaio C (2005) Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord 20:523-539. (Pubitemid 40862249)
24. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, et al. (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDSUPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129-2170. (Pubitemid 46382671)
25. Gravius A, Dekundy A, Nagel J, Morè L, Pietraszek M, and Danysz W (2008) Investigation on tolerance development to subchronic blockade of mGluR5 in models of learning, anxiety, and levodopa-induced dyskinesia in rats. J Neural Transm 115:1609-1619.
26. Gregoire L, Ouatara B, Gasparini F, Bilbe G, Johns DG, Vranesic I, Sahasramaman S, Gomez-Mancilla B, and diPaolo T (2009) Antidyskinetic effect of AFQ056 a novel metabotropic glutamate receptor type 5 (mGluR5) antagonist in MPTP monkeys. Soc Neurosci Abstr 35:326.319.
27. Gubellini P, Pisani A, Centonze D, Bernardi G, and Calabresi P (2004) Metabotropic glutamate receptors and striatal synaptic plasticity: implications for neurological diseases. Prog Neurobiol 74:271-300. (Pubitemid 39586720)
28. Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, Brotchie JM, and Standaert DG (2005) Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 48:503-516. (Pubitemid 40332408)
29. Hill MP, McGuire SG, Crossman AR and Brotchie JM (2001) The mGlu5 receptor antagonist SIB-1830 reduces L-DOPA-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Soc Neurosci Abstr 27:200.217.
30. Hung SW, Adeli GW, Arenovich T, Fox SH and Lang AE (2007) Patient perception of dyskinesias in Parkinson's disease. Neurology 68 (Suppl 1):64.
31. Institute of Laboratory Animal Resources (1996) Guide for the Care and Use of Laboratory Animals, 7th ed. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council, Washington, DC.
32. Konitsiotis S, Blanchet PJ, Verhagen L, Lamers E, and Chase TN (2000) AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54:1589-1595. (Pubitemid 30226801)
33. Lea PM 4th and Faden AI (2006) Metabotropic glutamate receptor subtype 5 antagonists MPEP and MTEP. CNS Drug Rev 12:149-166.
34. Levandis G, Bazzini E, Armentero MT, Nappi G, and Blandini F (2008) Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts L-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol Dis 29:161-168. (Pubitemid 350180490)
35. Marin C, Papa S, Engber TM, Bonastre M, Tolosa E, and Chase TN (1996) MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats. Brain Res 736:202-205. (Pubitemid 26356477)
36. Marino MJ, Awad H, Poisik O, Wittmann M, and Conn PJ (2002) Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia. Amino Acids 23:185-191.
37. McIldowie MJ, Gandy MN, Skelton BW, Brotchie JM, Koutsantonis GA, Spackman MA, and Piggott MJ (2010) Physical and crystallographic characterisation of the mGlu5 antagonist MTEP and its monohydrochloride. J Pharm Sci 99:234-245.
38. Mela F, Marti M, Dekundy A, Danysz W, Morari M, and Cenci MA (2007) Antagonism of metabotropic glutamate receptor type 5 attenuates L-DOPA-induced dyskinesia and its molecular and neurochemical correlates in a rat model of Parkinson's disease. J Neurochem 101:483-497. (Pubitemid 46525288)
39. Morin N, Gregoire L, Gomez-Mancilla B, Gasparini F, and Di Paolo T (2010) Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 58:981-986.
40. Nash JE, Ravenscroft P, McGuire S, Crossman AR, Menniti FS, and Brotchie JM (2004) The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp Neurol 188:471-479. (Pubitemid 38891607)
41. Nutt JG, Gunzler SA, Kirchhoff T, Hogarth P, Weaver JL, Krams M, Jamerson B, Menniti FS, and Landen JW (2008) Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov Disord 23:1860-1866.
42. Ossowska K, Konieczny J, Wardas J, Pietraszek M, Kuter K, Wolfarth S, and Pilc A (2007) An influence of ligands of metabotropic glutamate receptor subtypes on parkinsonian-like symptoms and the striatopallidal pathway in rats. Amino Acids 32:179-188. (Pubitemid 46198741)
43. Ossowska K, Konieczny J, Wolfarth S, and Pilc A (2005) MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology 49:447-455. (Pubitemid 41169969)
44. Pahwa R, Factor SA, Lyons KE, Ondo WG, Gronseth G, Bronte-Stewart H, Hallett M, Miyasaki J, Stevens J, Weiner WJ, et al. (2006) Practice Parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66:983-995. (Pubitemid 44044780)
45. Papa SM and Chase TN (1996) Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Ann Neurol 39:574-578. (Pubitemid 26146687)
46. Péchevis M, Clarke CE, Vieregge P, Khoshnood B, Deschaseaux-Voinet C, Berdeaux G, Ziegler M, and Trial Study Group (2005) Effects of dyskinesias in Parkinson's disease on quality of life and health-related costs: a prospective European study. Eur J Neurol 12:956-963. (Pubitemid 41820050)
47. Poewe W (2009) Treatments for Parkinson disease - past achievements and current clinical needs. Neurology 72:S65-S73.
48. Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe W, Stocchi F, Tolosa E, and LARGO study group (2005) Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 365:947-954.
49. Rylander D, Recchia A, Mela F, Dekundy A, Danysz W, and Cenci MA (2009) Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J Pharmacol Exp Ther 330:227-235.
50. Samadi P, Grégoire L, Morissette M, Calon F, Hadj Tahar A, Dridi M, Belanger N, Meltzer LT, Bédard PJ, and Di Paolo T (2008) mGluR5 metabotropic glutamate receptors and dyskinesias in MPTP monkeys. Neurobiol Aging 29:1040-1051. (Pubitemid 351697993)
51. Silverdale MA, Kobylecki C, Hallett PJ, Li Q, Dunah AW, Ravenscroft P, Bezard E, and Brotchie JM (2010) Synaptic recruitment of AMPA glutamate receptor subunits in levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate. Synapse 64:177-180.
52. Silverdale MA, Nicholson SL, Crossman AR, and Brotchie JM (2005) Topiramate reduces levodopa-induced dyskinesia in the MPTP-lesioned marmoset model of Parkinson's disease. Mov Disord 20:403-409.
53. Testa CM, Standaert DG, Landwehrmeyer GB, Penney JB Jr, and Young AB (1995) Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons. J Comp Neurol 354:241-252.
54. 1-Adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. J Pharmacol Exp Ther 328:276-283.
55. Westin JE, Vercammen L, Strome EM, Konradi C, and Cenci MA (2007) Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 62:800-810. (Pubitemid 47374647)